On November 4, 2026 ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, reported upcoming presentations describing the IND-enabling activities and therapeutic potential for IMGS-203, the company’s novel Stimulator of Interferon Genes (STING) Agonist, for the treatment of recurrent glioblastoma (GBM). These data will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting taking place from November 4-8, 2026, at the Phoenix Convention Center in Phoenix, AZ.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation Details:
Presentation Title:
IND-enabling nonclinical development of IMGS-203, a novel STING agonist, supports first-in-human translation in glioblastoma
Abstract No.:
839
Presenter:
Akash Boda, PhD, ImmunoGenesis
Presentation Date:
Friday, November 6, 2026
Presentation Time:
12:15 – 1:45 PM MT
Location:
PCC-North Building – Lower Level Exhibition Halls 4-5-6
Oral Presentation Details:
Presentation Title:
IND-enabling nonclinical development of IMGS-203, a novel STING agonist, supports first-in-human translation in glioblastoma
Abstract No.:
839
Presenter:
Akash Boda, PhD, ImmunoGenesis
Presentation Date:
Saturday, November 7, 2026
Presentation Time:
12:53 – 1:01 PM MT
Session:
204b: Rapid Oral – Clinical 2
Location:
PCC-West Building – 300 Level – 301BC
About IMGS-203
IMGS-203 is a novel STING agonist being developed by ImmunoGenesis as a cancer immunotherapy designed to stimulate antitumor immune responses. ImmunoGenesis plans to initially advance IMGS-203 into clinical development for recurrent glioblastoma (GBM), an aggressive and difficult-to-treat brain cancer with limited therapeutic options and significant unmet medical need.
(Press release, ImmunoGenesis, NOV 4, 2026, View Source [SID1234674219])